The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

NHS England has proposed a phased rollout of tirzepatide, a promising weight-loss drug, to benefit patients most likely to ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

NHS England has proposed a phased rollout of Eli Lilly’s obesity injection Mounjaro (tirzepatide), prioritizing patients with ...

Tirzepatide was granted approval from the Medicines and Healthcare products Regulatory Agency last November, while NICE ...

NHS leaders are considering a phased rollout of the obesity injection tirzepatide (Mounjaro, Eli Lilly) because of potentially high demand. The National Institute for Health and Care Excellence (NICE) ...

Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss ...

In a consultation the UK's drugs watchdog has now proposed the NHS expands its use for weight loss for those who are severely ...